High-flow oxygen and pro-serotonin agents for non-interventional treatment of post-dural-puncture headache

Am J Emerg Med. 2020 Dec;38(12):2625-2628. doi: 10.1016/j.ajem.2020.07.076. Epub 2020 Aug 3.

Abstract

Objective: Post dural puncture headache (PDPH) is a common complication in patients following diagnostic or therapeutic lumbar puncture, procedures requiring epidural access, and spinal surgery. Epidural blood patch (EBP), the gold standard for the treatment of this pathology requires training not provided to emergency physicians. In addition, the presence of concomitant pathology and abnormal laboratory values are contraindications to perform EBP. In presence of these limitations, we sought for a non-interventional management of PDPH utilizing high-flow oxygen and pro-serotonin agents. We reviewed the mechanism of action of this therapy METHODS: To illustrate our proposal, we report a series of twelve consecutive patients with PDPH treated with high-flow oxygen therapy at 12 L/min via a non-rebreathing mask and intravenous metoclopramide.

Results: All patients were treated with this conservative therapy, no adverse reactions were observed. After the intervention, the headache resolved without further indications for PDPH.

Conclusion: Our series suggests that combining high-flow oxygen and pro-serotonin agents such metoclopramide in the ED might be a feasible option as effective as the invasive methods used in treating PDPH. This therapy appears to be efficient and to minimize risk, cost and side effects. It presents an easily accessible alternative that should be considered when PDPH is not a viable option.

Keywords: Headache; High-flow oxygen; Post-dural puncture.

MeSH terms

  • Adult
  • Aged
  • Conservative Treatment
  • Female
  • Humans
  • Male
  • Metoclopramide / therapeutic use*
  • Middle Aged
  • Oxygen Inhalation Therapy / methods*
  • Post-Dural Puncture Headache / therapy*
  • Serotonin 5-HT3 Receptor Antagonists / therapeutic use*
  • Serotonin 5-HT4 Receptor Agonists / therapeutic use*
  • Treatment Outcome

Substances

  • Serotonin 5-HT3 Receptor Antagonists
  • Serotonin 5-HT4 Receptor Agonists
  • Metoclopramide